Medicure Inc. – OTC:MCUJF
Medicure stock price today
Medicure stock price monthly change
Medicure stock price quarterly change
Medicure stock price yearly change
Medicure key metrics
Market Cap | 9.32M |
Enterprise value | 5.55M |
P/E | 4.23 |
EV/Sales | 0.23 |
EV/EBITDA | 1.50 |
Price/Sales | 0.48 |
Price/Book | 0.54 |
PEG ratio | 0.04 |
EPS | -0.11 |
Revenue | 21.76M |
EBITDA | 522K |
Income | -1.16M |
Revenue Q/Q | 1.17% |
Revenue Y/Y | -5.29% |
Profit margin | 11.97% |
Oper. margin | 4.64% |
Gross margin | 65.8% |
EBIT margin | 4.64% |
EBITDA margin | 2.4% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMedicure stock price history
Medicure stock forecast
Medicure financial statements
| Jun 2023 | 5.99M | 253K | 4.22% |
|---|---|---|---|
| Sep 2023 | 5.00M | 84K | 1.68% |
| Dec 2023 | 5.07M | -1.54M | -30.53% |
| Mar 2024 | 5.69M | 51K | 0.9% |
| Jun 2023 | 29207000 | 7.96M | 27.26% |
|---|---|---|---|
| Sep 2023 | 28845000 | 6.97M | 24.19% |
| Dec 2023 | 28059000 | 8.16M | 29.09% |
| Mar 2024 | 28673000 | 8.16M | 28.49% |
| Jun 2023 | 593K | 0 | -75K |
|---|---|---|---|
| Sep 2023 | 386K | -115K | -74K |
| Dec 2023 | 927K | -128K | -72K |
| Mar 2024 | -132K | -87K | -76K |
Medicure other data
| Quarter | Transcript |
|---|---|
| Q2 2023 31 Jul 2023 | Q2 2023 Earnings Call Transcript |
| Q1 2023 29 May 2023 | Q1 2023 Earnings Call Transcript |
| Q4 2022 10 Apr 2023 | Q4 2022 Earnings Call Transcript |
| Q3 2022 25 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Albert David Friesen Ph.D. (1947) Founder, Chief Executive Officer & Chairman of the board | $259,360 |
-
What's the price of Medicure stock today?
One share of Medicure stock can currently be purchased for approximately $0.94.
-
When is Medicure's next earnings date?
Unfortunately, Medicure's (MCUJF) next earnings date is currently unknown.
-
Does Medicure pay dividends?
No, Medicure does not pay dividends.
-
How much money does Medicure make?
Medicure has a market capitalization of 9.32M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 5.94% to 21.69M US dollars.
-
What is Medicure's stock symbol?
Medicure Inc. is traded on the OTC under the ticker symbol "MCUJF".
-
What is Medicure's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers—Specialty & Generic industry.
-
How do i buy shares of Medicure?
Shares of Medicure can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Medicure's key executives?
Medicure's management team includes the following people:
- Dr. Albert David Friesen Ph.D. Founder, Chief Executive Officer & Chairman of the board(age: 78, pay: $259,360)
-
Is Medicure founder-led company?
Yes, Medicure is a company led by its founder Dr. Albert David Friesen Ph.D..
-
When Medicure went public?
Medicure Inc. is publicly traded company for more then 21 years since IPO on 19 Feb 2004.
-
What is Medicure's official website?
The official website for Medicure is medicure.com.
-
Where are Medicure's headquarters?
Medicure is headquartered at 2-1250 Waverley Street, Winnipeg, MB.
-
How can i contact Medicure?
Medicure's mailing address is 2-1250 Waverley Street, Winnipeg, MB and company can be reached via phone at +20 44 877412.
Medicure company profile:
Medicure Inc.
medicure.comOTC
0
Drug Manufacturers—Specialty & Generic
Healthcare
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers ReDS, a non-invasive medical device that offers measurement of lung fluid for the management of congestive heart failure. Further, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail pharmacies, as well as online. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.
Winnipeg, MB R3T 6C6
CIK: 0001133519
ISIN: CA58469E4085
CUSIP: 58469E408
